Can excessive testosterone cause clitoromegaly and reduced orgasmic intensity or difficulty achieving orgasm?

Can Excessive Testosterone Cause Clitoromegaly and Orgasm Difficulties?

Physiological doses of testosterone therapy do NOT cause clitoromegaly or reduced orgasm in women, but supraphysiological (excessive) doses can cause clitoromegaly while paradoxically impairing orgasmic function. 1

Clitoromegaly Risk

The 2019 Global Consensus Statement definitively establishes that systemic testosterone therapy in doses approximating physiological concentrations for premenopausal women is NOT associated with clitoromegaly 1. This represents Level I, Grade A evidence from meta-analyses of randomized controlled trials. The guideline explicitly states that physiological testosterone is associated only with mild increases in acne and body/facial hair growth in some women, but not with clitoromegaly, alopecia, or voice changes 1.

However, the critical caveat is that these safety findings do not apply to supraphysiological doses - specifically injectables, pellets, or formulations resulting in excessive blood testosterone concentrations 1. The evidence from anabolic androgenic steroid abuse confirms that excessive androgen exposure does cause clitoromegaly 2, along with menstrual irregularities and subfertility.

Key Threshold Considerations:

• Clitoromegaly develops when androgen exposure is truly excessive, not with replacement-dose therapy
• The clitoral index (product of sagittal and transverse diameters of the glans) becomes abnormal (>35 mm²) with pathological androgen excess 3
• Developmental studies show that if testosterone exposure occurs after 12 weeks gestation, only clitoromegaly occurs without other genital abnormalities 4

Orgasm and Sexual Function

The relationship between testosterone and orgasm is opposite to what the question implies. Rather than causing difficulty with orgasm, physiological testosterone therapy actually improves orgasmic function 1. The 2019 consensus demonstrates that testosterone therapy increases orgasmic function, along with sexual desire, arousal, pleasure, and responsiveness (Level I, Grade A) 1.

Recent research reveals complex, non-linear associations:

• Lower testosterone is associated with reduced orgasm frequency, not higher testosterone 5, 6
• In peri-postmenopausal women with orgasm difficulty, median testosterone levels were significantly lower (0.39 vs. 0.48 nmol/L) 6
• Non-linear thresholds exist, with markedly worse orgasm function below approximately 138 pmol/L measured free testosterone 5

The Paradox of Excessive Doses:

While physiological testosterone improves orgasm, supraphysiological doses from anabolic steroid abuse can impair reproductive function through different mechanisms 2:

• Profound suppression of endogenous gonadotropins (LH, FSH)
• Reduction in endogenous testosterone production
• Structural and functional changes in reproductive tissues
• These effects persist for weeks to months after discontinuation

Clinical Algorithm

If a patient presents with both clitoromegaly and orgasm difficulties:

1. Measure serum testosterone levels (preferably by LC-MS/MS, not immunoassay)

   • No cutoff blood level differentiates women with versus without sexual dysfunction in the physiological range 1
   • But supraphysiological levels confirm excessive exposure

2. Determine the source:

   • Exogenous: compounded preparations, excessive dosing, anabolic steroids
   • Endogenous: congenital adrenal hyperplasia, androgen-secreting tumors
   • The 2014 Endocrine Society guideline recommends monitoring testosterone levels every 6 months in women on therapy 7

3. If supraphysiological testosterone is confirmed:

   • Discontinue or reduce the source immediately
   • Clitoromegaly from excessive androgens may be irreversible 2
   • Gonadotropin suppression and sexual dysfunction typically recover over 13-24 weeks after discontinuation, though testosterone levels may remain suppressed longer 2

4. If testosterone levels are normal or low:

   • Clitoromegaly has other causes (congenital adrenal hyperplasia, tumors)
   • Orgasm difficulties are likely unrelated to testosterone excess and may benefit from testosterone therapy 1, 8

Critical Pitfalls

• Do not confuse physiological replacement with excessive dosing - the safety profile is completely different 1
• Compounded preparations are specifically excluded from safety recommendations due to unpredictable dosing 1
• The response to therapy does not correlate with testosterone levels in the physiological range 7, so measuring levels to optimize sexual function is not useful
• Clitoromegaly from true androgen excess is a bioassay of androgenic stimulation 3 and indicates pathological exposure, not therapeutic dosing